Roth MKM Maintains Buy on Mind Medicine, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff has maintained a Buy rating on Mind Medicine (MNMD) and increased the price target from $25 to $36.

March 07, 2024 | 4:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roth MKM analyst Jonathan Aschoff has reaffirmed a Buy rating on Mind Medicine and raised the price target from $25 to $36.
The increase in price target by a reputable analyst like Jonathan Aschoff suggests a strong bullish outlook on Mind Medicine. This is likely to instill confidence in investors about the company's future prospects, potentially leading to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100